Patients at risk of infection benefit from bone cement with a combination of antibiotics
COPAL® G+C bone cement containing two antibiotics has long been used for revisions after replacement of hip or knee joints. In hemiarthroplasty, the benefit of dual antibiotic-loaded bone cement is also seen in a reduction of infections after joint replacement in risk for infection patients. New retrospective studies now show that the use of COPAL® G+C with its combination of antibiotics for fixation of hip or knee joints in risk for infection patients can reduce the infection risk in primary arthroplasty and in aseptic revision arthroplasty of the knee.
More than 30% of patients have at least 2 risk factors
In the treatment of hip and knee joint prostheses, periprosthetic infection (PPI) is a feared complication that can be life threatening for patients and costly for hospitals. Individual patient risks can favour the development of a PJI. On average, more than 30% of patients had at least 2 risk factors. In some countries (Finland, Germany), this affects up to 50% of patients. These risk factors include obesity, diabetes and cardiovascular diseases as well as previous surgical procedures or infections.
34% reduction of infection risk in primary arthroplasty
According to a recent study, COPAL® G+C, a dual antibiotic-loaded bone cement, can reduce the frequency of periprosthetic infections in patients with risk factors after primary treatment of the knee or hip by 34% compared to a bone cement containing only one antibiotic. With hip joint replacement, COPAL® G+C was used if 3 or more risk factors were present. With knee joint replacement, COPAL® G+C was used if 2 or more risk factors were present.
57% reduction of infection risk in aseptic knee revision
The benefits of using dual-loaded bone cement (COPAL® G+C) to reduce PJI in risk for infection patients are also seen in cases of aseptic knee revision. A current study demonstrated a reduction of the infection risk for aseptic knee revisions of 57%.
You will find a list of the studies and further explanations here.
About Heraeus Medical
Heraeus Medical is a leader in bone cements and biomaterials for surgical orthopaedics and trauma surgery. This enables the company to make an important contribution to supporting surgeons and their surgical team and to improve medical outcomes. In the area of biomaterials, Heraeus Medical focuses on products for use in bone and joint surgery. The core product PALACOS® is considered the gold standard among bone cements and has continuously proven itself over six decades of clinical use. The first antibiotic bone cement for infection prophylaxis in arthroplasty was developed almost 50 years ago with PALACOS® R+G. The COPAL® product portfolio covers dual antibiotic-loaded bone cements and products for revision arthroplasty.
Heraeus, the technology group headquartered in Hanau, Germany, is a leading international family-owned portfolio company. The company’s roots go back to a family pharmacy started in 1660. Today, the Heraeus group includes businesses in the environmental, electronics, health and industrial applications sectors. Customers benefit from innovative technologies and solutions based on broad materials expertise and technological leadership. In the 2019 financial year, Heraeus generated revenues of €22.4 billion with approximately 14,900 employees in 40 countries. Heraeus is now one of the top 10 family-owned companies in Germany and holds a leading position in its global markets.
Heraeus Medical GmbH
Senior Manager Communication & Media Relations
Tel.: +49 6181-352995
Dr. Ludger Wess
Managing Partner, akampion
T: +49 (0)40 88 16 59 64
F: +49 (0)40 88 16 59 65
Managing Partner, akampion
T: +49 (0)30 23632768
F: +49 (0)30 23632769